Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#3918 Efficiency of GemCap + mitotane in platinum and mitotane resistant adrenocortical carcinoma

Introduction: Gemcitabine, metronomic capecitabine and mitotane (M) combination (GemCap + M) is the most investigated and widely used regimen in 2nd and subsequent lines therapy of advanced adrenocortical cancer (ACC). In the largest retrospective study (N=145) only 28% of patients (pts) reached therapeutic concentration of mitotane (M), which translated into a significant improvement in the median progression free survival (PFS).

Conference:

Presenting Author: Zhulikov Y

Authors: Zhulikov Y, Kovalenko E, Bokhyan V, Evdokimova E, Khoroshilov M,

Keywords: adrenocortical cancer, gemcitabine, capecitabine, GemCap, mitotane,

#2222 Biliary Mixed Neuroendocrine-Nonneuroendocrine Neoplasms: A Series of Four Cases with Review of Literature

Introduction: Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs) are rare tumors comprising of both adenocarcinoma and neuroendocrine component, at least 30% of each in the lesion.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Pande P

Authors: Pande P, Desai G, Shah R, Palepu J,

Keywords: minen, biliary mixed neuroendocrine-nonneuroendocrine neoplasms,

#1778 Chemotherapy for Pulmonary Large Cell Neuroendocrine Carcinomas: Does the Regimen Matter?

Introduction: Metastatic pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare disease and the most effective chemotherapy regimen is debated, i.e. small cell lung carcinoma (SCLC) or non-small cell lung carcinoma (NSCLC) chemotherapy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Derks J

Authors: Derks J, Suylen R, Thunnissen E, Den Bakker M, Groen H,

Keywords: lcnec, chemotherapy, nec, lung,

#1080 Evaluation of the Combination Oxaliplatin and 5-Fluorouracil or Gemcitabine in Patients with Metastatic Lung Carcinoid Tumors

Introduction: -

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: walter t

Authors: Walter T, Planchard D, Bouledrak K, Guigay J, Dussol A,

Keywords: gemox, folfox, lung, carcinoid,

#1067 Gemox or Alkylating Agents in Neuroendocrine Tumors? The Help of O6-Methylguanine-DNA Methyltransferase (MGMT) Status?

Introduction: Alkylating agents are the backbone chemotherapy in neuroendocrine tumors (NET). However, gemcitabine associated to oxaliplatine (gemox) has showed interesting activity in a small study.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Dussol A, Joly M, Hervieu V, Forestier J, Lombard-Bohas C,

Keywords: gemox, alkylating agent, MGMT,